IP Library › Granted Patent US 12,624,008
Granted Patent B2
US 12,624,008 · App. 18/081,793 · Granted May 12, 2026

4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD

Inventors: Nigel Ramsden (Babraham, GB); David John Fox (Babraham, GB); James Andrew Huntington (Altrincham, GB)
Assignee: CENTESSA PHARMACEUTICALS (UK) LIMITED
C07D239/36A61K31/513
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,624,008
App. No.
18/081,793
Granted
May 12, 2026
Kind
B2
Abstract

The invention relates to 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid, compositions thereof, and uses of either, for example in the treatment of α 1 -antitrypsin deficiency (A1AD or AATD).

Claims (7)

1 . A method of treating α 1 -antitrypsin deficiency (AATD) in a subject in need thereof, the method comprising administering to the subject in need thereof a compound represented by the structure of

or a pharmaceutically acceptable salt thereof; or

a pharmaceutical composition comprising a compound represented by the structure of

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

2 . The method of claim 1 , wherein the administering to the subject in need thereof induces Z α 1 -Antitrypsin (A1AT) secretion in the subject.

3 . The method of claim 1 , wherein the administering to the subject in need thereof increases levels of Z α 1 -Antitrypsin (A1AT) in the subject.

4 . The method of claim 1 , wherein the administering to the subject in need thereof is conducted orally.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2026
From: OXFORD FINANCE LLC
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 075069/0879 →
SECURITY INTEREST Recorded Dec 31, 2024
From: CENTESSA PHARMACEUTICALS (UK) LIMITED
To: OXFORD FINANCE LLC
Reel/Frame 069708/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2023
From: Z FACTOR LIMITED
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 065294/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2023
From: RAMSDEN, NIGEL; FOX, DAVID JOHN; HUNTINGTON, JAMES ANDREW
To: Z FACTOR LIMITED
Reel/Frame 065279/0038 →
Priority Claims (1)
GB 2009074 · Jun 15, 2020 · national
Continuity (2)
Continuation PCTGB2021051496 · Jun 15, 2021
Related Publication 20240327357A1 · Oct 3, 2024
References Cited (21)
US 8436013B2 · Liu et al. · 2013 [cited by applicant]
US 20070167621A1 · Durley · 2007 [cited by applicant]
US 20160340319A1 · Gnamm et al. · 2016 [cited by applicant]
WO WO2019243841A1 · 2019 [cited by applicant]
WO WO2020081257A1 · 2020 [cited by applicant]
WO WO2020120992A1 · 2020 [cited by applicant]
WO WO2021116706A1 · 2021 [cited by examiner]
WO WO2021255436A1 · 2021 [cited by applicant]
Berthelier et al. Discovery of an Inhibitor of Z-Alpha1 Antitrypsin Polymerization. PLoS One 10(5):e0126256 (May 11, 2015). [cited by applicant]
Bouchecareilh et al. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of a1-antitrypsin deficiency. J Biol Chem 287(45):38265-38278 (2012). [cited by applicant]
Burrows et al. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. PN… [cited by applicant]
CAS Registry Nos. 1797054-78-4 and 1219580-65-0 (Feb. 7, 2018). [cited by applicant]
Chang et al. Small-molecule peptides inhibit Z alpha1-antitrypsin polymerization. J. Cell. Mol. Med. 13(8B):2304-2316 (2009). [cited by applicant]
Elliott et al. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Science 9:1274-1281 (2000). [cited by applicant]
Huntington. How and why the Z variant of α [cited by applicant]
Huntington. How and why the Z variant of α [cited by applicant]
Knaupp et al. Kinetic instability of the serpin Z alpha1-antitrypsin promotes aggregation. J. Mol. Biol. 396:375-383 (2010). [cited by applicant]
Mallya et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 50(22):5357-5363 (2007). [cited by applicant]
Parfrey et al. Targeting a surface cavity of alpha 1-antitrypsin to prevent conformational disease. J. Biol. Chem. 278(35):33060-33066 (2003). [cited by applicant]
PCT/GB2021/051496 International Search Report and Written Opinion dated Aug. 24, 2021. [cited by applicant]
GB2009074.2 Search Report dated Nov. 23, 2020. [cited by applicant]